(4Z)-1-ethyl-4-[(1-ethylquinolin-1-ium-4-yl)methylidene]quinoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (4Z)-1-ethyl-4-[(1-ethylquinolin-1-ium-4-yl)methylidene]quinoline
• 化学式: C23H23N2+
• 分子量: 327.4
• InChiKey: PBYSOAALDIVUSK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  7.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• PHOSPHOR SHEET, WHITE LIGHT SOURCE DEVICE HAVING SAID PHOSPHOR SHEET, AND DISPLAY APPARATUS HAVING SAID WHITE LIGHT SOURCE DEVICE
  申请人：Dexerials Corporation

  公开号：EP3321718A1

  公开（公告）日：2018-05-16

  Disclosed are a phosphor sheet capable of improving color purity of each of RGB reproduced through a color filter, a white light source device including the phosphor sheet, and a display device including the white light source device. The disclosed phosphor sheet is a phosphor sheet for converting LED light into white light, including: a phosphor layer containing at least a phosphor and a resin; and a pair of transparent substrates sandwiching the phosphor layer, in which the phosphor sheet includes a coloring material having an absorption maximum wavelength of at least one of from 480 nm to 510 nm or from 570 nm to 620 nm.

  本发明公开了一种能够提高通过彩色滤光片再现的 RGB 各色彩纯度的荧光粉片、一种包括该荧光粉片的白光光源装置，以及一种包括该白光光源装置的显示装置。所公开的荧光粉片是一种用于将 LED 光转换为白光的荧光粉片，包括：至少含有荧光粉和树脂的荧光粉层；以及夹住荧光粉层的一对透明基板，其中荧光粉片包括一种着色材料，该材料的吸收最大波长至少为 480 纳米至 510 纳米或 570 纳米至 620 纳米中的一种。
• BINDING DOMAIN MAPPING
  申请人：George Mason Research Foundation, Inc.

  公开号：US20190033319A1

  公开（公告）日：2019-01-31

  The present disclosure relates to compositions and methodology for revealing binding sites between proteins, proteins and nucleic acids, or proteins and small molecules. The disclosure provides rapid and direct positive identification and sequencing of the contact region between such molecules, and can be applied to individual interacting pairs, as well as large-scale or global interactions.
• ANTI-NEURODEGENERATIVE DISEASE AGENT
  申请人：Hayashibara Co., Ltd.

  公开号：US20220031690A1

  公开（公告）日：2022-02-03

  The present invention addresses the problem of providing an orally-administrable anti-neurodegenerative disease agent having an action of accelerating neurocyte growth and an action of promoting neurite-outgrowth, and having excellent transfer properties to central nervous tissues. The problem is solved by providing an anti-neurodegenerative disease agent containing a compound represented by General formula 4 as an active ingredient, and having an action of accelerating neurocyte growth, an action of promoting neurite-outgrowth, and an action of scavenging reactive oxygen species. In General formula 4, R 10 and R 11 represent the same or different alkyl group having 2-8 carbon atoms, and the alkyl group may be either a straight chain or a branched chain. n represents an integer of 0 or 1, and X 4 − represents a suitable counter anion that is pharmaceutically acceptable.